Fig. 4: The combination therapy of Mcl-1 inhibitors with OSI906 suppresses MCL1-amplified OS tumor growth in vivo.
From: Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma
A Scheme of the combination therapy of MIK665 with OSI906 in vivo. B, C Relative tumor volume changes of NOS-10 (B) and NOS-1 (C) through the drug treatment. NOS-10 or NOS-1 cells are subcutaneously inoculated into immunodeficient SCID-beige mice (2.5 × 106 or 1 × 106 cells/mouse) and treated with 25 mg/kg of MIK665 intraperitoneally or 25 mg/kg of OSI906 orally three times a week. Arrowheads indicate timing of drug administration. All data are shown as mean ± SD (n = 5 or 6). D Scheme of the combination therapy of AZD5991 with OSI906 in vivo. E Relative tumor volume changes of NOS-10 through the drug treatment. NOS-10 cells are subcutaneously inoculated into SCID-beige mice (5 × 106 cells/mouse). AZD5991 and its vehicle control are intravenously administrated once a week. OSI906 and its vehicle control are orally administrated three times a week. Arrowheads indicate timing of drug administration. All data are shown as mean ± SD (n = 5). **p < 0.01, *p < 0.05 as determined by Mann–Whitney U test.
